Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of the intravenous drip
infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis
(IPF) in a multicenter, double-blind, randomized, placebo-controlled, parallel group
comparison study, and to confirm its superiority over placebo with survival rate on Day 90 as
the primary endpoint.